Introduction to the indications and clinical application of talquetamab-tgvs

Talquetamab is a new immunotherapy drug mainly used to treat patients with relapsed or refractory multiple myeloma (MM). The drug is an immunomodulator and works by targeting GPRC5D (G protein-coupled receptor 5D). Multiple myeloma is a common plasma cell malignant tumor that usually relapses gradually with treatment, making treatment extremely difficult for patients. Tacquitumab helps identify and attack cancer cells by activating the patient's immune system, and is particularly effective in patients who have already experienced at least four treatment regimens, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.

The clinical application of this drug has been approved by the U.S. Food and Drug Administration (FDA) and is listed as an orphan drug. It is mainly suitable for patients who have received traditional treatments many times and still cannot get effective relief. The use of Taquitutumab fills the treatment gap for patients with drug-resistant multiple myeloma, especially when conventional treatments have limited effects, and it provides patients with a new treatment option.

The mechanism of action of Taquitumumab is that it can target GPRC5D. This receptor is widely expressed in multiple myeloma cells. By binding to the GPRC5D receptor on the surface of tumor cells, it activates T cell immune responses and promotes the occurrence of anti-tumor immune responses, thereby effectively inhibiting tumor growth. In addition, Taquitumab's killing effect on myeloma cells is more precise, reducing damage to normal cells, and its side effects are milder than traditional treatment drugs.

As more and more clinical studies demonstrate its efficacy, tarquinatumumab provides a new treatment option for patients with relapsed and refractory multiple myeloma, which is of great significance, especially for those patients who have failed to benefit from other treatments.

Reference materials:https://www.talveyhcp.com/